Literature DB >> 14644020

Gonadotropin-releasing hormone antagonists.

Karen L Herbst1.   

Abstract

Hypothalamic gonadotropin-releasing hormone (GnRH) is a decapeptide that stimulates pituitary synthesis and secretion of gonadotropins and, therefore, gonadal hormones. GnRH antagonists, of which thousands have been formulated, inhibit the hormone from binding to its receptor, inducing a pharmacological hypophysectomy. Peptide derivations of GnRH and non-peptide compounds are both in clinical trials or approved for assisted reproduction. As these compounds reach the market, the use of antagonists might expand to treatment of other hormonally dependent diseases, hormonal male contraception and growth inhibition of extra-pituitary cancer cells expressing GnRH receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644020     DOI: 10.1016/j.coph.2003.06.009

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  10 in total

Review 1.  Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

2.  Hormone suppression with GnRH antagonist promotes spermatogenic recovery from transplanted spermatogonial stem cells in irradiated cynomolgus monkeys.

Authors:  G Shetty; R K Uthamanthil; W Zhou; S H Shao; C C Weng; R C Tailor; B P Hermann; K E Orwig; M L Meistrich
Journal:  Andrology       Date:  2013-09-30       Impact factor: 3.842

3.  Gonadotropins regulate rat testicular tight junctions in vivo.

Authors:  Mark J McCabe; Gerard A Tarulli; Sarah J Meachem; David M Robertson; Peter M Smooker; Peter G Stanton
Journal:  Endocrinology       Date:  2010-03-31       Impact factor: 4.736

Review 4.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

5.  Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics.

Authors:  John Kenneth Amory; Thomas W Leonard; Stephanie T Page; Edel O'Toole; Michael J McKenna; William J Bremner
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-29       Impact factor: 3.333

6.  Effects of suppressing gonadal hormones on response to novel objects in adolescent rats.

Authors:  De-Laine M Cyrenne; Gillian R Brown
Journal:  Horm Behav       Date:  2011-09-02       Impact factor: 3.587

7.  The stereoselectivity and hydrolysis efficiency of recombinant D-hydantoinase from Vigna angularis Against 5-benzylhydantoin derivatives with halogen and methyl substituents.

Authors:  Gniewomir Latacz; Katarzyna Kieć-Kononowicz
Journal:  Appl Biochem Biotechnol       Date:  2014-10-24       Impact factor: 2.926

8.  GnRH Antagonist Improves Pubertal Cyclophosphamide-Induced Long-Term Testicular Injury in Adult Rats.

Authors:  Rongrong Xie; Linqi Chen; Haiying Wu; Ting Chen; Fengyun Wang; Xiuli Chen; Hui Sun; Xiaozhong Li
Journal:  Int J Endocrinol       Date:  2018-06-10       Impact factor: 3.257

Review 9.  Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.

Authors:  Maira Huerta-Reyes; Guadalupe Maya-Núñez; Marco Allán Pérez-Solis; Eunice López-Muñoz; Nancy Guillén; Jean-Christophe Olivo-Marin; Arturo Aguilar-Rojas
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

10.  Amyloid as a depot for the formulation of long-acting drugs.

Authors:  Samir K Maji; David Schubert; Catherine Rivier; Soon Lee; Jean E Rivier; Roland Riek
Journal:  PLoS Biol       Date:  2008-02       Impact factor: 8.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.